CKPT (Checkpoint Therapeutics) Other Financing : $-2.25 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Other Financing?

Checkpoint Therapeutics's Other Financing for the three months ended in Dec. 2024 was $0.00 Mil.

Checkpoint Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.25 Mil.

Checkpoint Therapeutics Other Financing Historical Data

The historical data trend for Checkpoint Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Other Financing Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Financing

Get a 7-Day Free Trial

-2.02

-1.01

-2.73

6.83

6.78

Checkpoint Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Financing	Get a 7-Day Free Trial															-	-1.21	-	-1.04	-

Checkpoint Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.25 Mil.

Checkpoint Therapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

CZTA:Germany

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Executives

Oliviero James F Iii	director, officer: CEO, President and Director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
William Garrett Gray	officer: See Remarks	2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon	director	C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman	director	464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen	director	2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020